Breast cancer and pregnancy: How safe is trastuzumab?

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background. A 29-year-old woman was diagnosed with lymph-node-positive, steroid-hormone-receptor-negative and HER2/neu-positive breast cancer. She underwent surgery followed by cyclophosphamide, epirubicin, and 5-fluorouracil chemotherapy, and received radiotherapy followed by trastuzumab therapy for 1 year. During the tenth month of trastuzumab therapy, the patient reported a missed period and had a positive pregnancy test. Investigations. Physical examination, pregnancy test, echocardiography. Diagnosis. Unintended pregnancy during adjuvant trastuzumab therapy. Management. Cessation of trastuzumab and close monitoring of mother and fetus during pregnancy.

Original languageEnglish
Pages (from-to)367-370
Number of pages4
JournalNature Reviews Clinical Oncology
Volume6
Issue number6
DOIs
Publication statusPublished - 2009

Fingerprint

Breast Neoplasms
Pregnancy Tests
Pregnancy
Epirubicin
Steroid Receptors
Fluorouracil
Cyclophosphamide
Physical Examination
Echocardiography
Fetus
Radiotherapy
Therapeutics
Lymph Nodes
Mothers
Hormones
Drug Therapy
Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Breast cancer and pregnancy : How safe is trastuzumab? / Azim, Hatem A.; Peccatori, Fedro A.; Liptrott, Sarah J.; Catania, Chiara; Goldhirsch, Aron.

In: Nature Reviews Clinical Oncology, Vol. 6, No. 6, 2009, p. 367-370.

Research output: Contribution to journalArticle

@article{f2dc1ee5f5b64f3f9c3f2e210cb3cfe0,
title = "Breast cancer and pregnancy: How safe is trastuzumab?",
abstract = "Background. A 29-year-old woman was diagnosed with lymph-node-positive, steroid-hormone-receptor-negative and HER2/neu-positive breast cancer. She underwent surgery followed by cyclophosphamide, epirubicin, and 5-fluorouracil chemotherapy, and received radiotherapy followed by trastuzumab therapy for 1 year. During the tenth month of trastuzumab therapy, the patient reported a missed period and had a positive pregnancy test. Investigations. Physical examination, pregnancy test, echocardiography. Diagnosis. Unintended pregnancy during adjuvant trastuzumab therapy. Management. Cessation of trastuzumab and close monitoring of mother and fetus during pregnancy.",
author = "Azim, {Hatem A.} and Peccatori, {Fedro A.} and Liptrott, {Sarah J.} and Chiara Catania and Aron Goldhirsch",
year = "2009",
doi = "10.1038/nrclinonc.2009.48",
language = "English",
volume = "6",
pages = "367--370",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Breast cancer and pregnancy

T2 - How safe is trastuzumab?

AU - Azim, Hatem A.

AU - Peccatori, Fedro A.

AU - Liptrott, Sarah J.

AU - Catania, Chiara

AU - Goldhirsch, Aron

PY - 2009

Y1 - 2009

N2 - Background. A 29-year-old woman was diagnosed with lymph-node-positive, steroid-hormone-receptor-negative and HER2/neu-positive breast cancer. She underwent surgery followed by cyclophosphamide, epirubicin, and 5-fluorouracil chemotherapy, and received radiotherapy followed by trastuzumab therapy for 1 year. During the tenth month of trastuzumab therapy, the patient reported a missed period and had a positive pregnancy test. Investigations. Physical examination, pregnancy test, echocardiography. Diagnosis. Unintended pregnancy during adjuvant trastuzumab therapy. Management. Cessation of trastuzumab and close monitoring of mother and fetus during pregnancy.

AB - Background. A 29-year-old woman was diagnosed with lymph-node-positive, steroid-hormone-receptor-negative and HER2/neu-positive breast cancer. She underwent surgery followed by cyclophosphamide, epirubicin, and 5-fluorouracil chemotherapy, and received radiotherapy followed by trastuzumab therapy for 1 year. During the tenth month of trastuzumab therapy, the patient reported a missed period and had a positive pregnancy test. Investigations. Physical examination, pregnancy test, echocardiography. Diagnosis. Unintended pregnancy during adjuvant trastuzumab therapy. Management. Cessation of trastuzumab and close monitoring of mother and fetus during pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=68549135367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549135367&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2009.48

DO - 10.1038/nrclinonc.2009.48

M3 - Article

C2 - 19483741

AN - SCOPUS:68549135367

VL - 6

SP - 367

EP - 370

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 6

ER -